Health Care • Biotechnology: Pharmaceutical Preparations
$32.89 ▼ -1.07
(-3.15%)
MKT CAP: $3.17B • VOL: 1.62M
52W L $27 52W H $43
IDYA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $218.7M | $7.0M | $23.4M |
| YoY Revenue Growth % | +3024.4% | -70.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$159.3M | -$327.0M | -$134.4M |
| Operating Margin % | -72.8% | -80.0% | -80.0% |
| Net Income (GAAP) | -$113.7M | -$274.5M | -$113.0M |
| EBITDA (Normalized) | -$157.4M | -$323.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$71.1M | -$247.6M | -$115.2M |
| Capital Expenditures (CapEx) | $2.4M | $3.9M | — |
| Free Cash Flow (FCF) | -$73.5M | -$251.4M | -$115.2M |
| FCF Margin % | -33.6% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -13.8% | -26.5% | — |
| Cash & Short-Term Equivalents | $112.8M | $84.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.02B | $1.06B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IDYA.